Video

New superbug reaches the U.S.

CDC officials are working with health authorities to identify how the patient may have contracted the bacteria, including reviewing recent hospitalizations and other healthcare exposures


Researchers have found a person in the United States carrying bacteria resistant to antibiotics of last resort, according to an article on The Washington Post website.

Researchers worry that its colistin-resistance gene, known as mcr-1, could spread to other bacteria that can already evade other antibiotics.

Colistin is the antibiotic of last resort for particularly dangerous types of superbugs, including CRE, which health officials call a “nightmare bacteria.” 

CDC officials are working with health authorities to identify how the patient may have contracted the bacteria, including reviewing recent hospitalizations and other healthcare exposures.

Read the article.

 



June 7, 2016


Topic Area: Industry News


Recent Posts

Dirty Floors: How Pathogens Can Accumulate and Spread Underfoot

Studies show that healthcare floors are covered in bacteria and can quickly spread throughout patient rooms. 


WellSpan Health Opens Its Newberry Hospital in Pennsylvania


Cahaba Center for Mental Health Ensnared in Data Breach

On March 28, 2025, Cahaba identified suspicious activity in an employee email account.


Reframing the Construction Manager as a Community Manager

Managers must work with patients, community residents and other interested parties to ensure a smooth, successful construction projects


Health First Celebrates 'Topping Off' Ceremony for New Cape Canaveral Hospital Campus

Construction is slated to finish by the end of 2026 or early 2027.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.